CompletedPhase 3NCT04113187

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

Studying Hereditary hemorrhagic telangiectasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Bordeaux
Principal Investigator
Anne CONTIS, MD
University Hospital, Bordeaux
Intervention
Propranolol treatment(drug)
Enrollment
15 target
Eligibility
18 years · All sexes
Timeline
20202022

Study locations (1)

Collaborators

AMRO-HHT-France - Association Maladie de Rendu-Osler

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04113187 on ClinicalTrials.gov

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

See all trials for Hereditary hemorrhagic telangiectasia

← Back to all trials